<DOC>
	<DOCNO>NCT00952445</DOCNO>
	<brief_summary>The purpose study determine repeat daily dos T0903131 ( INT131 ) Besylate 4 week low fast blood glucose patient Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>A Safety Efficacy Study T0903131 ( INT131 ) Besylate Treat Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Clinical Diagnosis Type 2 Diabetes Mellitus least 3 month prior enrollment Fasting Plasma Glucose 126 240 mg/dL HemoglobinA1c ( HbA1c ) 6.8 % 10.0 % Fasting Cpeptide &gt; 0.8 ng/mL Treatment pharmacotherapy Type 2 Diabetes Mellitus within previous 6 week prior screen Prior treatment Thiazolidinedione , include Troglitazone , Rosiglitazone , pioglitazone BMI &gt; 42 kg/m2 Presence diabetic complication require chronic therapy Presence history form hepatic disease Serum creatinine &gt; 1.8 mg/dL History cardiac arrhythmia abnormal cardiac electrophysiology Any reason , Investigator 's judgment , would interfere ability subject comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>